| Mr Nathan W Gibbons, LCSW | |
|
2005 N 900 E, Provo, UT 84602-1763 | |
| (801) 422-5609 | |
| (801) 422-0856 |
| Full Name | Mr Nathan W Gibbons |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 2005 N 900 E, Provo, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508910092 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 992679 (Colorado) | Secondary |
| 1041C0700X | Social Worker - Clinical | 322256-3501 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Nathan W Gibbons, LCSW 4601 Spruce Cir, Cedar Hills, UT 84062-7703 Ph: (801) 216-4434 | Mr Nathan W Gibbons, LCSW 2005 N 900 E, Provo, UT 84602-1763 Ph: (801) 422-5609 |
News Archive
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.
Instead of a doctor seeing patients mostly when they're sick -; and the physician is getting paid for that visit or service -; this program gives financial rewards to practices that use a team of doctors, nurses and other staff to treat the whole person on a continuing basis, not just for one illness. ... The state initiative is among dozens of public and private experiments across the country that are trying to fundamentally change the way doctors practice medicine.
"The size of the population with disabilities is rather surprising," said Ralph Bangs, codirector of the Urban and Regional Research Program in Pitt's Center for Social and Urban Research (UCSUR), who coauthored the study with José René Argueta, a Pitt Ph.D. candidate in political science.
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
› Verified 6 days ago
Dallas Bean, Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 750 N 200 W Ste 300, Provo, UT 84601 Phone: 801-373-4760 | |
Brenna Garrett, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Mrs. Karen Dee Amsden, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 750 N Freedom Blvd, Provo, UT 84601 Phone: 801-373-4760 | |
Mr. John Paul Lilly, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 286 S 600 E, Suite C, Provo, UT 84606 Phone: 801-377-8232 Fax: 801-377-0930 | |
Frederick Brewer, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 750 N Freedom Blvd, Suite 108, Provo, UT 84601 Phone: 801-373-7394 | |
William Kory Camp, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4215 | |
Alaina Barrick, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4045 N Canyon Rd, Provo, UT 84604 Phone: 859-582-0032 |